Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)

• DOI: 10.1007/s40744-021-00423-8
• Publication Date: 2022-01-18T09:17:50Z
• Authors: Blanca Hernández-...; José Rosas; César Díaz-Torné; Joaquín Belzunegui; Rosario García-Vi...; José Inciarte-Mundo; Ana Pons; Ana M. Millán; Sicylle Jeria-Nav...; Jesús A. Valero; Noelia García-Cas...; Cristina Valero; Irene Llorente; Alberto Calvo; Silvia Díaz-Cerezo; Mercedes Núñez
• Keywords: Clinical Practice

Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved to treat rheumatoid arthritis (RA). This study aimed investigate patients' characteristics, prescription patterns, effectiveness, and treatment persistence in patients receiving baricitinib real-world practice Spain.This retrospective longitudinal cohort conducted five rheumatology units included adults with RA initiating (Sep-2017-May-19) at least a 6-month-follow-up. Demographic/clinical changes disease activity pain level were collected until discontinuation/end of follow-up. Treatment was estimated by Kaplan-Meier methods.Data from 182 (mean (SD)): 83.5% women, 62.2 (12.3) years, body mass index 26.8 (5.1), duration 13.2 (10.8) years Charlson Comorbidity Index score 2.4 (2.0). All had received one conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) before starting 78.0% biologic (bDMARD). Furthermore, 90.1% started 4 mg/day; 43.4% monotherapy. One hundred twelve (61.5%) continued data collection time; mean 14.1 (0.5) months. Overall 79.7/64.8/59.1% 6/12/18 Seventy (38.5%) discontinued during follow-up due loss efficacy (68.6%) or adverse events (18.6%). In those available scores the different observed cut-off points, remission low reported 71.6 76.3% 6/12 months any index: Disease Activity Score 28 joints using erythrocyte sedimentation rate (DAS28-ESR) (73.1 73.5%), Simplified (SDAI) (62.4 75.0%), Clinical (CDAI) (66.7 78.1%). Good moderate European League Against Rheumatism (EULAR)-response noted 80.0 78.2% patients, respectively. Improvement baseline (Visual Analog Scale) 2.5 cm 3.0 months, respectively.This Spanish treated long-standing refractory disease. Nevertheless, high improvements found 6 12 after initiation, independently composite measure used, reinforcing effectiveness routine clinical practice.